



SAFETY DATA SHEET

Revision date: 20-Aug-2014

Version: 2.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Pegvisomant for Injection

Trade Name: Somavert
Synonyms: Human Growth Hormone; HG; B2036-PEG; Pegvisomantum
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product for the treatment of growth hormone overproduction (acromegaly).

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

EU Classification:

EU Indication of danger: Toxic to Reproduction: Category 3

EU Risk Phrases:

R63 - Possible risk of harm to the unborn child.

Label Elements

Signal Word: Warning
Hazard Statements: H361d - Suspected of damaging the unborn child
May form combustible dust concentrations in air

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Pegvisomant for Injection
Revision date: 20-Aug-2014

Page 2 of 8
Version: 2.0



Other Hazards
Australian Hazard Classification (NOHSC):

No data available
Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Pegvisomant	218620-50-9	Not Listed	Repr.Cat.3;R63	Repr. 2,H361d	35-52

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Sodium Phosphate Monobasic, Monohydrate	10049-21-5	Not Listed	Not Listed	Not Listed	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	Not Listed	Not Listed	*
Mannitol	69-65-8	200-711-8	Not Listed	Not Listed	*
Glycine	56-40-6	200-272-2	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

SAFETY DATA SHEET

Material Name: Pegvisomant for Injection
Revision date: 20-Aug-2014

Page 3 of 8
Version: 2.0

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

SAFETY DATA SHEET

Material Name: Pegvisomant for Injection
Revision date: 20-Aug-2014

Page 4 of 8
Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Pegvisomant

Pfizer OEL TWA-8 Hr: 60µg/m³

Glycine

Latvia OEL - TWA 5 mg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Lyophilized powder plus sterile diluent	Color:	White
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

Pegvisomant

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

SAFETY DATA SHEET

Material Name: Pegvisomant for Injection
Revision date: 20-Aug-2014

Page 5 of 8
Version: 2.0

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the active ingredient
Long Term: Animal studies indicate that this material may cause adverse effects on the developing fetus.
Known Clinical Effects: Adverse effects most commonly reported in clinical use include gastrointestinal disturbances, changes in liver function, flu-like syndrome, fatigue, nausea, diarrhea and flatulence. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Drugs of this class may cause formation of antibodies, changes in blood sugar.

Acute Toxicity: (Species, Route, End Point, Dose)

Pegvisomant

Mouse	Subcutaneous	Discriminating Dose	10 mg/kg
Mouse	Para-periosteal	Discriminating Dose	10mg/kg
Non-human Primate	Intravenous	Discriminating Dose	100mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Pegvisomant

Skin Irritation	Rabbit	Non-irritating
Antigenicity- Passive cutaneous anaphylaxis	Mouse	Mild
Antigenicity- Passive cutaneous anaphylaxis	Monkey	Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Pegvisomant

14 Day(s)	Mouse	Intravenous	3 mg/kg/day	NOAEL	Liver
14 Day(s)	Mouse	Subcutaneous	3 mg/kg/day	LOAEL	Blood, Liver
28 Day(s)	Monkey	Subcutaneous	3 mg/kg/day	NOAEL	No effects at maximum dose
6 Month(s)	Rat	Subcutaneous	10 mg/kg/day	NOAEL	Blood, Liver, Kidney
6 Month(s)	Monkey	Subcutaneous	0.3 mg/kg/week	NOAEL	Bone Marrow

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Pegvisomant

Embryo / Fetal Development	Rabbit	Subcutaneous	10 mg/kg/day	NOAEL	Negative
Fertility and Embryonic Development	Rabbit	Subcutaneous	3 mg/kg/day	NOAEL	Fetotoxicity
Embryo / Fetal Development	Rabbit	Subcutaneous	10 mg/kg/day	NOAEL	Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

SAFETY DATA SHEET

Material Name: Pegvisomant for Injection
Revision date: 20-Aug-2014

Page 6 of 8
Version: 2.0

11. TOXICOLOGICAL INFORMATION

Pegvisomant

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

SAFETY DATA SHEET

Material Name: Pegvisomant for Injection
Revision date: 20-Aug-2014

Page 7 of 8
Version: 2.0

15. REGULATORY INFORMATION

WHMIS hazard class:
Class D, Division 2, Subdivision A



Pegvisomant

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Sodium Phosphate Monobasic, Monohydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Sodium phosphate, dibasic

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-448-7

Mannitol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-711-8

Glycine

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-272-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

SAFETY DATA SHEET

Material Name: Pegvisomant for Injection
Revision date: 20-Aug-2014

Page 8 of 8
Version: 2.0

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Toxic to Reproduction: Category 3

R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 20-Aug-2014

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet